Dihexa Research Guide: HGF Modulator, Synaptogenesis Biology, and Cognitive Enhancement Research

By Justin Cartier

Dihexa is a small lab-made peptide that research studies for memory and brain repair. The reason is its unusual talent. It drives the growth of new brain connections through the HGF/c-Met system.^[1] It came out of Washington State University as an orally active version of angiotensin IV. It ramps up the formation of new synapses and dendrites in the hippocampus, the brain’s memory hub.^[3] And it does that at doses far below what its parent compound needs. In animal models of memory loss, it pushed maze performance back toward young-control levels. It also reversed chemically induced memory deficits.

This guide covers what dihexa is used for in research. It explains how the compound engages the HGF/c-Met pathway to build new connections. It reviews what the rodent studies show on Alzheimer’s and other brain diseases. It also covers the open questions around human testing, side effects and safety, and what to check when sourcing material.

Research-use note: dihexa is a research compound, not a medicine. Everything below is for laboratory research and education only, not human use.

What is the peptide dihexa used for?

Mostly it is a research tool for two things. One is studying the HGF/c-Met system in the brain. The other is testing whether a memory-booster candidate can help in rodent models of brain disease. The published applications spread wide. They cover Alzheimer’s models, including chemically induced memory loss and aged-rat decline. They also cover Parkinson’s models, with motor recovery in lesioned rats, plus traumatic brain injury and general aging-related cognitive function research. No health regulator has cleared it for use in people, so it stays a laboratory research compound.

How does dihexa work in the brain?

The core move is boosting the HGF/c-Met system. Benoist and colleagues, in the Journal of Pharmacology and Experimental Therapeutics, showed dihexa binds tightly to hepatocyte growth factor (HGF). That sharpens HGF’s ability to switch on the c-Met receptor sitting on neurons.^[1] Notice the subtlety there. It doesn’t bind c-Met directly at all. Instead, it helps HGF and its receptor work together.

From there, the downstream signals travel through the familiar growth pathways, PI3K-Akt and Ras-MAPK. Those pathways drive brain plasticity, new dendritic spines, and the machinery that actually assembles synapses. Wright and Harding, in the Journal of Alzheimer’s Disease, argue that this genuine growth of dendrites and synapses is a real neurotrophic and neuroprotective effect.^[2] That’s what sets dihexa apart from the brain-chemistry-based boosters.

And its effect per dose is where things get striking. Benoist and colleagues, in an earlier study of Nle1-angiotensin IV analogs, found the cognitive benefits come from building synaptic connections.^[3] And it does that at concentrations far below what the parent angiotensin IV needs. That jump in potency runs orders of magnitude in places. It traces back to the chemical tweaks that made it stable and able to cross the blood-brain barrier.

What makes dihexa unique among cognitive peptides?

Three features really set it apart, and the first is the headline one. It works by mouth. Most peptides get shredded in the gut. But McCoy and colleagues, in the Journal of Pharmacology and Experimental Therapeutics, characterised dihexa as an orally active, blood-brain-barrier-crossing, metabolically stable peptide. That makes it one of very few orally active research peptides going.^[4] The second feature follows from that. Its small size and chemical build let it slip into the brain, which most peptides simply can’t manage. The third is raw potency. Its effects show up at far lower concentrations than the parent angiotensin IV, the biggest potency jump anywhere in this peptide family. So stack it against Semax (BDNF, nasal), Selank (GABA-A, nasal), and Cerebrolysin (a mixed cocktail, by injection). Dihexa stands alone in working orally while running on a single, well-mapped pathway.

Dihexa in Alzheimer’s and neurodegenerative disease research

Alzheimer’s research is really where dihexa built its name. Wright and colleagues, in Progress in Neurobiology, showed the compound holds promise for both memory and motor problems. It gets there by building synaptic connections in rodent models.^[5] It restored performance on several memory tasks, including the Morris water maze, novel object recognition, and the Y-maze. That held true in aged rats and in Alzheimer’s mouse models alike.

The Parkinson’s work then adds motor recovery to that memory story. In lesioned rats, dihexa could restore motor function and help dopamine neurons survive. The traumatic brain injury research tacks on spatial-memory recovery too. What’s satisfying is that the mechanism stays the same across all of them. HGF/c-Met activation builds new synapses in the neurons that survive. That partly makes up for the neuron loss that drives the disease in the first place.

Has dihexa been tested on humans?

Barely, and that’s the honest answer. Human testing is limited and mostly lives outside the peer-reviewed literature. No registered Phase 1 or Phase 2 trial has been completed. The compound has turned up in compounded clinical settings in the United States since the mid-2010s. That generated anecdotal but decidedly unsystematic human data on memory and brain-injury recovery. The absence of formal trials is the crucial gap here. Don’t assume human safety from the rat data alone.

Is dihexa FDA-approved or legal?

Dihexa has no FDA or Health Canada approval for any use. It is sold only as a research chemical for laboratory work. It isn’t on the World Anti-Doping Agency banned list as of 2026. One wrinkle is dihexa-specific. Compounded prescription use in some US states sits in a genuine legal gray area. Our guide to buying peptides in Canada covers what that research-only status means for sourcing.

Dosing and routes of administration

Published rat studies run dihexa by mouth at 0.1 to 2 mg/kg a day. Others use subcutaneous injection at 0.05 to 0.5 mg/kg a day. The oral route is the preferred one for long protocols, thanks to that gut stability.^[4] Human research-protocol doses have landed in the 8 to 45 mg a day range, based on rat-to-human scaling. It comes either as a powder for oral capsules or as a freeze-dried powder for injection.

How soon do dihexa effects appear?

In rodent models, measurable cognitive effects show up within 7 to 14 days of repeated dosing. The markers of new connections, dendritic spine density and PSD-95, climb within 5 to 10 days. Full histological recovery of dendrites in aged rats takes longer, 4 to 8 weeks of steady treatment. Because the mechanism is structural, the effects build up over time. They don’t deliver the next-day jolt of a brain-chemistry smart drug.

Benefits and side effects

On the upside, the reported benefits in rodent research include better spatial memory and motor-function recovery in lesion models. Researchers also report more dendritic spines and sharper thinking in aged animals. The side effects in rat studies are mild, mostly some occasional gut upset at high oral doses. There is no liver or heart signal at standard doses. The missing piece, again, is long-term human safety. With no formal human trials, safety past the rodent timescale simply isn’t characterized.

How much does dihexa cost?

Research-grade dihexa runs pricier than the mass-market boosters, mainly because it’s harder to make. Typical research-grade pricing in Canada and the United States sits around CAD 100 to 200 per 20 to 30 mg vial as of 2026, varying with each supplier’s purity standards. That cost reflects synthesis difficulty rather than scarcity. HPLC-verified material at 98 percent purity or higher costs more than lower-grade stock, which really shouldn’t be used in research at all.

Skip the guesswork on quality and order research peptides in Canada from a supplier that verifies every lot.

How do I know a dihexa batch is pure and correctly made?

Match the batch paperwork to dihexa’s known mass. Dihexa is a small modified peptide (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) with a molecular weight near 535 Da. So mass spectrometry on a genuine batch should read close to that figure. HPLC purity should be 98 percent or higher, with the chromatogram trace shown. Ask for a Certificate of Analysis from a testing lab outside the supplier rather than a generic sheet. For any live-animal or cell work, add endotoxin and sterility testing. Low-grade material that misses the expected mass or purity shouldn’t be used in research at all.

Reviv Peptides supplies dihexa in research-grade format with a third-party COA and HPLC purity confirmation. View the Reviv Peptides shop for current availability.

Dihexa questions

What is the peptide dihexa used for?

It’s used in research as an HGF/c-Met activator. Researchers use it to study new brain connections and memory in rodent models of Alzheimer’s, Parkinson’s, and traumatic brain injury.^[1][5] It isn’t approved for any use.

How much does dihexa cost?

Research-grade dihexa typically costs CAD 100 to 200 per 20 to 30 mg vial as of 2026. HPLC-verified 98 percent material costs more than lower-grade material.

Is dihexa peptide legal?

Dihexa is treated as a research chemical in Canada and the US. It may be sold for laboratory research only. Health Canada and the FDA have not approved it, and it isn’t on the WADA banned list.

Has dihexa been tested on humans?

No registered Phase 1 or Phase 2 trial has been completed. It’s been used in compounded clinical settings in the United States since the mid-2010s. But the systematic human data is limited.

What are the potential benefits of dihexa?

In rodent research: better spatial memory, motor-function recovery in lesion models, more dendritic spines, and sharper thinking in aged animals. The effects appear over weeks of dosing rather than acutely.

Key data point: Benoist and colleagues (2011, JPET) showed dihexa builds new synaptic connections and improves spatial memory. It does that at concentrations far below those its parent compound needs.^[3] That is why it’s one of the most potent cognitive research peptides per dose.

Summary

Dihexa is an unusually potent cognitive research peptide. It was developed at Washington State University as an orally active version of angiotensin IV. It works through the HGF/c-Met system to build new brain connections in the hippocampus at very low doses.^[1][3] Its strongest research uses sit in Alzheimer’s, Parkinson’s, and traumatic brain injury rodent models.^[5] That combination of oral activity, brain access, and high potency is what makes it such a valuable research tool. Human clinical data, though, is essentially absent, and the compound is sold for laboratory research only.

Further reading: Best nootropic peptides for cognitive research.

Sources: [1] Procognitive and synaptogenic effects depend on the HGF/c-Met system (Benoist et al., 2014), PubMed. [2] Brain HGF/c-Met system as a target in Alzheimer’s disease (Wright & Harding, 2015), PubMed. [3] Hippocampal synaptogenesis and spatial memory from Nle1-angiotensin IV analogs (Benoist et al., 2011), PubMed. [4] Metabolically stabilized angiotensin IV analogs as procognitive agents (McCoy et al., 2013), PubMed. [5] Small-molecule angiotensin IV analogs for Alzheimer’s and Parkinson’s (Wright et al., 2015), PubMed.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.